StreetInsider.com News Articles

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

Thu, 10 Sep 2026 08:05:00 -0400

– Post-hoc analysis shows YCANTH^® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –

WEST CHESTER, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on YCANTH^® (VP-102), a therapy approved by the FDA to treat molluscum contagiosum in patients 2 years of age and older, and VP-315, in development for basal cell carcinoma, at two upcoming dermatology conferences

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

Thu, 10 Sep 2026 08:05:00 -0400

– Post-hoc analysis shows YCANTH^® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28^th Annual Global Investment Conference.

H.C. Wainwright 28^th Annual Global Investment Conference
Event details:
Date: Monday, September 14, 2026
Time: 1:00pm ET
Location: New York, NY

Participants may access a live webcast of the event by clicking the link here.

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

H.C. Wainwright 28^th Annual Global Investment Conference
Event details:
Date: Monday, September 14, 2026
Time: 1:00pm ET
Location: New York, NY

Participants may access a live webcast of the event by clicking the link here.

Verrica completes enrollment in YCANTH wart trial, data due Q1 2027

Thu, 27 Aug 2026 08:00:28 -0400

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced it has completed enrollment in its first pivotal Phase 3 clinical trial, COVE-2, evaluating YCANTH® (VP-102) for the treatment of common warts, with topline data expected in the first quarter of 2027.

An interim statistical power analysis conducted by an independent statistician confirmed that no additional patients are recommended for full enrollment. The study remains blinded to the company and study team.

The second pivotal Phase 3 trial, COVE-3, has exceeded 50% of its current target enrollment, with topline data expected by mid-2027. COVE-3 is enrolling patients in the U.S. and Japan, while COVE-2 enrolled patients

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Thu, 27 Aug 2026 08:00:00 -0400

– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment –

– Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 –

WEST CHESTER, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced completion of enrollment of the first pivotal clinical trial (COVE-2) of its global Phase 3 program

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

Thu, 27 Aug 2026 08:00:00 -0400

– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment –

– Second pivotal Phase 3 trial (COVE-3) has already exceeded 50% of current target enrollment, with topline data currently expected in mid-2027 –

Lake Street Starts Verrica Pharmaceuticals (VRCA) at Buy

Thu, 27 Aug 2026 07:56:58 -0400

Lake Street analyst Thomas Flaten initiates coverage on Verrica Pharmaceuticals (NASDAQ: VRCA) with a Buy rating and a price target of $9.00.

For an analyst ratings summary and ratings history on Verrica Pharmaceuticals click here. For more ratings news on Verrica Pharmaceuticals click here.

Shares of Verrica Pharmaceuticals closed at $4.91 yesterday.

Lake Street Starts Verrica Pharmaceuticals (VRCA) at Buy

Thu, 27 Aug 2026 07:56:58 -0400

Lake Street analyst Thomas Flaten initiates coverage on Verrica Pharmaceuticals (NASDAQ: VRCA) with a Buy rating and a price target of $9.00.

For an analyst ratings summary and ratings history on Verrica Pharmaceuticals click here. For more ratings news on Verrica Pharmaceuticals click here.

Shares of Verrica Pharmaceuticals closed at $4.91 yesterday.

Form 4 Verrica Pharmaceuticals For: Aug 17 Filed by: Rosenberg Noah L.